Navigation Links
BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Date:5/8/2008

d pharmacokinetic profile of BCX-4208. Secondary objectives include assessment of pharmacodynamic measures and clinical response. The planned interim analysis of the Phase IIa trial included 30 patients divided evenly across the three study arms. The safety analysis includes follow-up on all 30 patients. Of the 30 patients evaluated for efficacy, 18 patients completed all 6 weeks of dosing. The 12 patients who discontinued prior to completing 6 weeks of dosing were equally distributed across the three arms of the study.

In an ongoing Phase I multiple ascending dose study, BCX-4208 showed a dose response effect on reducing lymphocyte counts at doses up to 1040mg administered once daily for 7 days. Interim data from the ongoing Phase IIa study at 20mg and 120mg showed similar dose-dependant effects on reduction of peripheral blood lymphocyte counts. Affected lymphocyte subsets in the Phase II study included CD4+, CD8+, CD56+, and CD20+ cells.

"While Roche's decision is disappointing, we are very encouraged by the effects on lymphocyte counts that we are seeing with BCX-4208. Similar activity with other experimental and marketed drugs has been associated with clinical efficacy in the treatment of various autoimmune diseases. Together with the good safety and tolerability profile of BCX-4208 observed to date, these data provide a strong scientific rationale for continuing to explore the activity of BCX-4208 in the treatment of autoimmune diseases," Mr. Stonehouse commented. "We look forward to evaluating the final data from the full cohort of 66 subjects later this year."

Conference Call and Webcast

The Company will sponsor a conference call at 8:30 a.m. Eastern Time on May 8, 2008 to discuss the financial results and the status of each of our programs in more detail. This call is open to the public and can be accessed live either over the Internet from http://www.biocryst.com or by dialing
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
2. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
3. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
4. BioCryst to Present at UBS 2007 Global Life Sciences Conference
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
7. Dendreon Reports First Quarter 2008 Financial Results
8. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Oncothyreon Reports First Quarter 2008 Financial Results
11. iCAD Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... studies for its newly developed Bruton,s tyrosine kinase ... been completed. The results of these preclinical evaluations ... Drug Administration. The feedback received from the Agency ... first-in-human study. Additional preclinical work is required to ...
(Date:2/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has ... Trypsin" report to their offering. , ... comprehensive data on Trypsin globally and regionally ( Europe ... America , Latin America etc.). ... This report focuses on three primary areas; manufacture ...
(Date:2/27/2015)... 27, 2015 The fully automated ... UC) can sequentially analyze up to 48 samples ... high-sensitivity detection of targets by mass spectrometry. ... fulfill the measurement requirements of a wide range ... drug delivery and search for disease biomarkers, additives ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Global Market Report of Trypsin 2014-2018 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
... Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... Scientific Corporation (NYSE: BSX ) has ... with left main coronary disease who were treated ... SYNTAX-LE MANS is a substudy of the landmark ...
... ( http://www.gene2drug.com ) -- the ... science industry -- announces the publication of its latest ... for Commercial Suppliers, Vol. III." Given the highly ... report is designed to create opportunities for differentiation by ...
... Cholesterol Test for determining heart disease riskBIRMINGHAM, Ala., May ... developer of the VAP Cholesterol Test, has announced it ... and report apolipoprotein B100 (apoB) using the Vertical Auto ... of the VAP Cholesterol Test to accurately report apoB, ...
Cached Biology Technology:SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 2SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 3SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 4SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 5BioInformatics, LLC New Report -- The Market for Antibodies: Keys to Success for Commercial Suppliers, Vol. III 2Atherotech Receives Patent for ApoB Measurement 2Atherotech Receives Patent for ApoB Measurement 3
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... PITTSBURGH, Oct. 23 A new study suggests that viruses ... cells while promoting the growth of surviving cells with cancerous ... wiping out normal cells that support the replication of viruses ... their circuitry. When this process is repeated over and over, ...
... David Jones, a fisheries oceanographer at the Cooperative Institute for ... Miamis Rosenstiel School, set out to design a better light ... invention would contribute to the discovery of a new species. ... known description, his catch turned out to be the answer ...
... Captains Log originally used with individuals diagnosed ... learning disabilities is being adapted to rehabilitate ... Michael Boivin, a Michigan State University associate ... and Bruno Giordani, a University of Michigan associate ...
Cached Biology News:Study proposes new theory of how viruses may contribute to cancer 2New light trap captures larval stage of new species; DNA barcode technology used 2MSU researcher helps develop computer game for Ugandan children recovering from cerebral malaria 2
...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... is a protein ribonuclease inhibitor that noncovalently binds ... inhibition is seen with RNase 1, T1, T2, ... from human placental ribonuclease inhibitor in that it ... does not release active RNase in the absence ...
... Inkjet Printer) is a revolutionary new ... Protein Macroarray Analysis, developed in conjunction ... strategy compliments established protocols in resolving ... proteins isoelectric point and apparent molecular ...
Biology Products: